Biotech trading was lively, with a few small caps surging on clinical and commercial updates, one name sliding after an unexpected change of direction and two companies adding cash in very different ways. The eight updates below vary widely in certainty. Some bring cash or insurance coverage, while others are early signals that still need execution. Here is what moved, why, and what to watch next.

OPKO Health (NASDAQ: OPK): Closes Up 18% at $1.61

OPKO Health agreed to sell targeted BioReference Health Business units to Labcorp for $722 million in upfront cash, with potential earnouts of up to $150 million tied to 4Kscore sales targets. Total consideration could reach $872 million, subject to customary regulatory clearances.

The upfront payment is the firm part and a substantial balance-sheet catalyst. The earnouts depend on 4Kscore sales, so they are possible upside rather than guaranteed cash. The sale also streamlines OPKO toward biopharmaceutical development, so investors should watch how the proceeds are used.

Estrella Immunopharma (NASDAQ: ESLA): Closes Up 68% at $0.53

Estrella activated a fifth clinical trial location for its Phase 1/2 STARLIGHT-1 study of EB103 in relapsed or refractory B-cell non-Hodgkin's lymphoma. The extra site broadens recruitment capacity, and the active expansion cohort is gathering safety and efficacy outcomes that will guide the design of a pivotal trial.

A new site is an operational step, not a data readout, so the size of the move says more about the low share price than about the news. The key catalyst is the expansion cohort data. At $0.53, the stock also trades below Nasdaq's $1.00 minimum bid level, which can raise listing questions.

SciSparc (NASDAQ: SPRC): Closes Down 45% at $2

SciSparc announced a strategic pivot into Agentic AI technologies, covering financial applications and cybersecurity, moving past its primary focus in biotechnology. Agentic AI refers to software agents that can plan and carry out tasks with limited human input.

There is currently no commercial agreement, Acquisition or Revenue contribution, so the shift is purely exploratory. The market reaction shows how a change of direction without a deal can unsettle holders who bought a biotech story. Any valuation effect depends on future monetization and execution, so investors should look for partners, terms and the Capital the new plan will need.

Dermata Therapeutics (NASDAQ: DRMA): Closes Up 37% at $0.91

Dermata shared favorable results from an open-label aesthetic evaluation of 31 subjects using its Tome Foundational Treatment. Over 71% showed overall visible skin enhancement after a single session, with broader benefits after four weekly procedures.

The results support commercial plans for Tome, but a small, unblinded study carries limited clinical weight, since participants and investigators know the treatment being given. Near-term catalysts depend on direct consumer adoption and retail performance, not on trial data. Like Estrella, the stock trades below $1.00.

Niki BioSolutions (NASDAQ: NIKI): Closes Up 3% at $2.22

Niki entered a strategic collaboration with the Global Alzheimer's Platform Foundation to deliver plasma APOE profiling for the Bio-Hermes-002 study cohort. The work expands genetic screening across a deeply characterized patient population.

Commercial details were not disclosed. The agreement enhances exposure for DiamiR's state-approved test platform and could speed future diagnostic partnerships and institutional adoption. The modest 3% move fits an update with no stated revenue. Investors should wait for paid follow-on agreements.

NeurAxis (NYSE: NRXS): Closes Up 19% at $7.74

NeurAxis obtained expanded medical policy coverage for IB-Stim from a prominent national payer. The decision adds approximately 26 million lives and takes total covered individuals past 147 million.

For an FDA-cleared neuromodulation therapy, reimbursement reach is a key commercial hurdle, so this is a meaningful step. Upside still depends on turning broader insurance access into provider adoption and sales, which investors can track through quarterly revenue.

Valion Bio (NASDAQ: VBIO): Closes Down 15% at $1.23

Valion Bio reached an early feasibility milestone for LarmorBio's BioScan-NMR platform. NMR signal outputs aligned closely with microbial cell-density measurements during fermentation runs.

The result offers preliminary proof of concept for real-time, non-invasive process monitoring, which could help distinguish Velocity Bioworks' CDMO capabilities. Functional scalability and commercial value remain unverified, which helps explain why the stock fell despite positive news.

CDT Equity (NASDAQ: CDT): Closes Down 13% at $0.21

CDT disclosed that its affiliate Sarborg filed a solid-form Patent application covering a novel respiratory candidate aimed at an addressable market above $20 billion a year. The filing strengthens Sarborg's intellectual property to support future licensing.

CDT holds a 22.7% stake in Sarborg. Its 1,290 shares are valued at roughly $161 million based on Sarborg's most recent private financing round, but the position is private and illiquid. A patent application is not a granted patent, and the stake is only worth what a buyer or licensee will pay.

Recursion Pharmaceuticals (NASDAQ: RXRX): Closes Up 11% at $4.16

Recursion priced an underwritten public offering of 61.54 million Class A common shares at $3.25 each, for roughly $200 million in gross proceeds. The cash bolsters the Balance Sheet and supports its AI-driven discovery pipeline.

The cost is dilution, since the new equity spreads ownership across more shares. The offering price sits below the $4.16 close, so buyers in the deal hold a gain on paper. Investors should watch which pipeline milestones the funding is meant to reach.

The Common Thread

Cash arrived in two forms. OPKO is being paid for a business it is selling, while Recursion is selling new shares. Several updates, including Estrella, Dermata and NeurAxis, are operating steps whose value depends on later data or sales. Three names, Estrella, Dermata and CDT, trade below $1.00, where large percentage moves can come from small price changes and Listing Rules can matter.

Key Highlights

  • OPKO's up to $872 million exit: Labcorp pays $722 million upfront plus up to $150 million in 4Kscore earnouts, and shares closed up 18% at $1.61.
  • Estrella leads the gainers: A fifth STARLIGHT-1 site lifted the stock 68% to $0.53, though expansion cohort data is the real catalyst.
  • SciSparc slumps 45%: The Agentic AI pivot has no deal, agreement or revenue behind it yet.
  • Recursion raises $200 million: 61.54 million shares at $3.25 fund its AI discovery pipeline at the cost of dilution.
  • Coverage and data, with caveats: NeurAxis reaches over 147 million covered lives, while Dermata's 31-subject study is small and unblinded.

Disclaimer: This content is for information only and is not financial advice or a recommendation to buy or sell any security. Biotech and micro-cap stocks carry high risk, including loss of capital. Please do your own research or consult a licensed adviser.